Armstrong Quoted On Health Reform Areas To Watch For Pharma Industry

MedAd News

Mark Armstrong, a Member of the Firm in the Health Care and Life Sciences practice of Epstein Becker Green Wickliff & Hall in Houston, was quoted on three areas to watch in the pharmaceutical industry as the health care debate progresses.

In the article, "Peril and Promise of Healthcare Reform," Armstrong pointed out where there is likely to be change: "I would not be surprised if there were some discounts that were given during the coverage gap or the donut hole in Medicare Part D. I wouldn't be surprised if there were some increased rebates that were directed toward the Medicaid program, both for the brand name drugs and the generic drugs. And there may be provisions that would pass giving the government greater enforcement opportunities in fraud, waste, and abuse as it pertains to healthcare providers, including pharmaceutical manufacturers."